Our look is new. Our purpose is the same. Learn more about our brand evolution.
The Global FSHD Innovation Hub is dedicated to speeding up the development of treatments for facioscapulohumeral muscular dystrophy (FSHD) and ensuring patients get access to them as soon as possible. It serves as a one-stop partner for biopharmaceutical companies, providing specialized support throughout the entire drug development process.
The FSHD research community faces key challenges, including limited trial capacity, slow site start-up, and difficulty identifying expert trial sites. Additionally, many patients worldwide may struggle to access new therapies due to rigid insurance policies and a lack of real-world data. The Hub tackles these challenges head-on by offering expert-driven, purpose-built solutions that bridge the gap between research, clinical trials, and patient access to treatments.
The Global FSHD Innovation Hub is a subsidiary of the FSHD Society and includes as partners TRiNDS (a neuromuscular-focused CRO) and Lumiio (a health technology and data platform) to provide unmatched expertise in FSHD therapy development.
